

# LITERATURA

## Monografie

1. Beneš P. Základy umělé výživy. Nutriční péče pro nemocniční praxi. Praha: Maxdorf; 1999.
2. Broulík P, Osteoporóza a její léčba. 2nd ed. Praha: Maxdorf; 2009.
3. Brunová J, Bruna J. Klinická endokrinologie. Praha: Maxdorf; 2009.
4. Češka R, et al. Cholesterol a ateroskleróza, léčba dyslipidemií. 2nd ed. Praha: Triton; 2012.
5. Fejfarová V, Jirkovská A, et al. Léčba syndromu diabetické nohy odlehčením. Praha: Maxdorf; 2015.
6. Hainer V. Základy klinické obezitologie. 2nd ed. Praha: Grada Publishing; 2011.
7. Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ, editors. Textbook of Diabetes. 5th ed. Wiley-Blackwell; 2017.
8. Jabor A, et al. Vnitřní prostředí. Praha: Grada Publishing; 2008.
9. Jirkovská A, et al. Jak (si) léčit a kontrolovat diabetes. Manuál pro edukaci diabetiků. Praha: Mladá fronta; 2015.
10. Jirkovská A, et al. Syndrom diabetické nohy. Komplexní týmová péče. Praha: Maxdorf; 2006.
11. Jirkovská A, Jirkovská J, Čechová K, Havlová V et al. Skupinová edukace diabetiků. Jak na to. Praha: Geum; 2017.
12. Jirkovská A. Léčba diabetu inzulinovou pumpou. 3th ed. Brno: Medatron; 2004.
13. Kunešová M. Základy obezitologie. Praha: Galén; 2016.
14. Lebl J, Zapletalová J, Koloušková S. Dětská endokrinologie. Praha: Galén; 2003.
15. Saudek F. Transplantační léčba diabetu. Praha: Maxdorf; 2010.
16. Sklenář Z, Ščigel V. Magistraliter receptura ve stomatologii. 2nd ed. Praha: ČSK; 2013.
17. Sobotka L, Allison SP, Furst P, Maier R, Pertkiewitz M, Soeters P. Basics in clinical nutrition. Praha: Galén; 2004.
18. Sosna T et al. Diabetická retinopatie – diagnostika, prevence, léčba. 2nd ed. Praha: Axonite; 2016.
19. Stárka L, Zamrazil V, et al. Základy klinické endokrinologie. 2nd ed. Praha: Maxdorf; 2005.
20. Svačina Š. Klinická dietologie. Praha: Grada Publishing; 2009.
21. Škrha J. Diabetologie. Praha: Galén; 2009.
22. Zadák Z. Výživa v intenzivní péči. 2nd ed. Praha: Grada Publishing; 2008.
23. Zamrazil V, Pelikánová T. Akutní stavy v endokrinologii a diabetologii. Praha: Galén; 2007.

## Standardní postupy a doporučení

1. ADA Standards of medical care in diabetes – 2018. Diabetes Care. 2018;41 Suppl 1.
2. ADA. Lifestyle management. Nutrition. Diabetes Care. 2018;Suppl 1:S38–S51.
3. ADA. Obesity management for the treatment of Type 2 diabetes. Diabetes Care. 2016;39(Suppl 1):S47–S51.
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the Study of Obesity. Circulation. 2009;120(16):1640–5.
5. Bakker K, Apelqvist J, Lipsy B, et al.; International Working Group on the Diabetic Foot (IWGDF). Prevention and management of Foot Problems in Diabetes. Guidance Documents and Recommendations 2015. www.iwgdf.org.



6. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al.; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016 Oct 14;37(39):2999–3058.
7. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*. 2017 Dec;40(12):1631–40.
8. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016. *Eur Heart J* (2016) <https://www.escardio.org/Guidelines-&Education/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure>.
9. Filipovský J, Widimský J Jr, Ceral J, Cífková R, Horký K, Linhart A, et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiovaskulární prevence*. 2012;3:1–16.
10. IDF. *Diabetes Atlas 2017*. 8th ed. International Diabetes Federation; 2017.
11. Jabor A. Nomenklatura glykohemoglobinů. *Encyklopedie laboratorní medicíny pro klinickou praxi – speciál 2008*. In: Jabor A, editor. Vnitřní prostředí. Praha Grada; 2008.
12. Jirkovská A, Lacigová S, Rušavý Z, Bém R; ČDS JEP. Doporučený postup pro prevenci, diagnostiku a terapii syndromu diabetické nohy. [www.diab.cz](http://www.diab.cz).
13. Jirkovská A, Pelikánová T, Anděl M; Výbor ČDS. Doporučený postup dietní léčby pacientů s diabetem. *DMEV*. 2012;15:235–43.
14. Jirkovská A. Syndrom diabetické nohy. *Medicína po promoci*. 2018;19:14–9.
15. Kanis JA, McCloskey EV, Johansson H, et al. European Guidance for the Diagnosis and Management of Osteoporosis in Postmenopausal Women. *Osteoporos Int*. 2013;24:23.
16. *Kidney Disease: Outcomes Quality Initiative (KDOQI)*. National Kidney Foundation. 2002.
17. Kirkman MS, et al. Diabetes in Older Adults: A Consensus Report. *J Am Geriatr Soc*. 2012;60:2342–2356.
18. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. *J Hypertension*. 2013;31:1281–357.
19. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. *Clin Chem Lab Med*. 2007;45(8):1077–80.
20. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia*. 1986 Jan;29(1):46–52.
21. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A position Statement by the American Diabetes Association. *Diabetes Care*. 2017;40(1):136–54.
22. Rosa J, Blahoš J, Bayer M., Broulík P, Horák P, Kasalický P, et al. Osteoporosis in males. Statement of the Czech Society for Metabolic Bone Diseases. *Osteol Bull*. 2016;21(2):42–48.
23. Rosa J, Šenk F, Palička V; Výbor Společnosti pro metabolická onemocnění skeletu. Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy 2015. <http://www.smos.cz>.
24. Schaper N, Van Netten J, Apelqvist J, et al. Prevention and management of foot problems in diabetes: A summary guidance for daily practice 2015, based on the IWGDF guidance documents. *Diabetes Res Clin Pract*. 2017;124:84–92.
25. Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. *Immunol Today*. 1995 Jun;16(6):289–94.
26. Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L; European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. *Diabetes Metab*. 2011 Nov;37 Suppl 3:S27–38.
27. Standardy péče o diabetes mellitus 2. typu. Standardy České diabetologické společnosti. 2017 ([www.diab.cz](http://www.diab.cz)). *Diabetologie, metabolismus, endokrinologie, výživa*. 2017.
28. Svačina S, Jurašková B, Karen I, Šmahelová A, Olšovský J, Červený R, Holmerová I, Pelikánová T. Doporučení pro péči o starší nemocné s diabetem v ČR. *Vnitřní Lékařství*. 2013 Dec;59(12):1088–95.
29. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. *Calcif Tissue Int*. 2009;84:45–55.



**Studie**

1. 4S (Scandinavian Simvastatin Survival Study) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. *Lancet*. 1994 Nov 19;344(8934):1383–9.
2. ACCOMPLISH (Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension) Jamerson KA; The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events. *J Clin Hypertens (Greenwich)*. 2003 Jul–Aug;5(4 Suppl 3):29–35.
3. ACCORD (Action to Control Cardiovascular Risk in Diabetes) Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008 Jun 12;358(24):2545–59.
4. ADAG (HbA1c-derived Average Glucose) Kuenen J. How do the HbA1c values relate to Mean Blood Glucose Concentrations? Results of the ADA-EASD multicentre study. Consensus statement on the worldwide standardization of the HbA1c measurement. EASD Annual meeting 2007, Amsterdam, 18-Sep-07. *Diabetologia*. 2007;50:2042–3.
5. ADOPT (A Diabetes Outcome Progression Trial) Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. *N Engl J Med*. 2006;355:2427–43.
6. ADVANCE ON. Zoungas S, Chalmers J, Neal B. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes *N Engl J Med* 2014; 371:1392–1406
7. ADVANCE. The ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008, 358(24):2560–72.
8. BARI2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) Trial) Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009, 360(24):2503–2515.
9. Bosh J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. *N Engl J Med*. 2006 Oct 12;355(15):1551–62. Epub 2006 Sep 15.
10. CALDIRET. Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2009 Apr 18;373(9672):1364–71.
11. CANVAS Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017 Aug 17;377(7):644–57.
12. CARDS Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet*. 2004 Aug 21–27;364(9435):685–96.
13. CARE (Cholesterol And Recurrent Events) Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. *N Engl J Med*. 1996;335:1001–09.
14. DAIS (Diabetes Atherosclerosis Intervention Study) Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes. *Lancet*. 2001;357:905–10.
15. DAMAD (Dipyridamol Aspirin Microangiopathy of Diabetes Study). Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. *Diabetes*. 1989 Apr;38(4):491–8.
16. DCCT (Diabetes Control and Complications Trial). The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N Engl J Med*. 1993 Sep; 329(14).
17. DESMOND (Diabetes Education and Self Management Programme) Khunti K, Gray LJ, Skinner T et al. Effectiveness of a diabetes education and self management programme (DESMOND)



- for people with newly diagnosed type 2 diabetes mellitus: free year follow-up of cluster randomised controlled trial in primary care. *BMJ*. 2012;344:e2333.
18. DEVOTE Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*. 2017;377:723–732
  19. DIGAMI (Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction) Malmberg K. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J*. 2005 Apr;26(7):650–61.
  20. DIRECT (Diabetic Retinopathy Candesartan Trials) <http://clinicaltrials.gov/ct2/show/NCT-00252720>
  21. DPP (2) (Diabetes Prevention Program) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. *Diabetes*. 2005 Aug;54(8):2404–14.
  22. DPP (Diabetes Prevention Program) Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002, 346(6):393–403.
  23. DREAM (The Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Gerstein HC, Yusuf S, Bosh J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. *Lancet*. 2006 Sep 23;368(9541):1096–105.
  24. DRS (Diabetic retinopathy study) Diabetic retinopathy study. <http://www.nei.nih.gov/neitrials/viewStudyWeb.aspx?id=62>.
  25. EDIC/DCCT (Epidemiology of Diabetes Interventions and Complications; Diabetes Control and Complications Trial) Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005 Dec 22;353(25):2643–53.
  26. ELIXA Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in evaluation of lixisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *Am Heart J*. 2015;169:631–638 e637
  27. EMPAREG OUTCOME Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015.
  28. EMPAREG RENAL Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.; Investigators E-RO. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375:323–334.
  29. ETDRS (Early Treatment Diabetes Retinopathy Study). Photocoagulation for diabetic macular edema. *Arch Ophthalmol*. 1985;103:1796.
  30. EUCLID (EURODIAB Controlled Trial of Lisinopril in Insulin Dependent Diabetes) Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients. *Diabetes*. 1998 Sep;47(9):1507–11.
  31. EURODIAB Amione C, Giunti S, Fornengo P, Soedamah-Muthu SS, Chaturvedi N, Fuller JH, Barutta F, Gruden G, Bruno G. Incidence of prolonged QTc and severe hypoglycemia in type 1 diabetes: the EURODIAB Prospective Complications Study. *Acta Diabetol*. 2017 Sep;54(9):871–876.
  32. EXAMINE White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369:1327–1335.
  33. EXSCEL (Exenatide Study of Cardiovascular Event Lowering) Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). *Am Heart J*. 2017 May;187:1–9.



51. ORIGIN Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med.* 2012;367:319–328.
52. PARADIGM- HF. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin versus enalapril in heart failure. *N Engl J Med.* 2014;371:993–1004.
53. PIPOD (Pioglitazone In Prevention Of Diabetes) Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. *Diabetes.* 2006 Feb;55(2):517–22.
54. PROACTIVE (3) (PROspective PioglitAzone Clinical Trial In MacroVascular Events Study) Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROACTIVE Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROACTIVE (PROspective pioglitAzone Clinical Trial In macro-Vascular Events 03). *Stroke.* 2007 Mar;38(3):865–73.
55. PROACTIVE (PROspective PioglitAzone Clinical Trial In MacroVascular Events Study) Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD et al: Secondary prevention of macrovascular events in patients with type 2 diabetes. *Lancet* 2005, 366(9493):1279–1289.
56. RECORD (Rosiglitazone evaluated for cardiovascular outcomes) Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009, 373(9681):2125–2135.
57. REVEAL Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med.* 2017;377:1217–1227.
58. RIO LIPIDS (Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia) Despres JP. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N Engl J Med.* 2005 Nov 17;353(20):2121–4.
59. SAVOR-TIMI 53 Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med.* 2013;369:1317–1326.
60. SCOUT (Sibutramine Cardiovascular Outcomes Trial) Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al.; on the behalf of the SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. *Eur Heart J.* 2007 Dec;28(23):2915–23.
61. SENIORS: Flather MD, Shibata MC, Coats AJ et al. The SENIORS Investigators. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J.* 2005;26(3):215–225.
62. SHHS (Sleep Heart Health Study) Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'Connor GT, et al. The Sleep Heart Health Study: design, rationale, and methods. *Sleep.* 1997 Dec;20(12):1077–85.
63. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. *Eur Heart J.* 2011;32(15):1900–8.
64. STENO-2 Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008, 358(6):580–591.
65. STOP-NIDDM (Acarbose for prevention of type 2 diabetes mellitus) Chiasson JL, et al. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance. *Endocr Pract.* 2006 Jan–Feb;12 Suppl 1:25–30, *JAMA.* 2003;290:486–94. *Lancet* 2002, 359(9323):2072–2077.
66. SUSTAIN 6 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, et al.; Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2016;375:1834–1844.



34. EXSCEL Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:1228–1239.
35. FATS (Familial Atherosclerosis Treatment Study) Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. 1990;323:1289–98.
36. FHS (Framingham Heart (Off springs) Study) Framingham heart study. <http://www.nhlbi.nih.gov/about/framingham/>.
37. FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomized controlled trial. *Lancet*. 2005;366(9500):1849–61.
38. GISSI-Prevenzione (Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients with Acute Myocardial Infarction) Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. *Circulation*. 1997 Dec 16;96(12):4239–45.
39. HAPO (Hyperglycemia and Adverse Pregnancy Outcome Study) HAPO Study Cooperative Research Group. *Int J Gynaecol Obstet*. 2002 Jul;78(1):69–77.
40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008, 359(15):1577–1589.
41. HPS (Heart Protection Study) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. *Lancet*. 2003;361:2005–16.
42. JELIS (Japan EPA Lipid Intervention Study) Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al.; Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis*. 2008 Sep;200(1):135–40. Epub 2008 Jun 19. Erratum in: *Atherosclerosis*. 2009 May;204(1):233.
43. LEAD-6 (Liraglutide Effect and Action in Diabetes) Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009 Jul 4;374(9683):39–47.
44. LEADER Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; Investigators LT. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–322.
45. LIPIDS (Long-term Intervention with Pravastatin in Ischaemic Disease Study). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998; 339:1349–57.
46. MDRD (Modification of diet in renal disease) Klahr S. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *N Engl J Med*. 1994 Mar 31;330(13):877–84.
47. MONICA WHO Project (Monitoring Trends and Determinants in Cardiovascular Disease) Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. *Lancet*. 1999 May 8;353(9164):1547–57.
48. NHANES (National Health and Nutrition Examination Survey) National Health and Nutrition Examination Survey. <http://www.cdc.gov/nchs/nhanes.htm>.
49. ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) <http://clinicaltrials.gov/ct2/show/NCT00153101>.
50. ORIGIN (Outcome Reduction with Initial Glargine Intervention) Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia. *Am Heart J*. 2008 Jan;155(1):26–32, 32.e1–6.



67. TECOS Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373:232–242.
68. TIMAD (Ticlopidine Microangiopathy of Diabetes Study). Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. *Arch Ophthalmol*. 1990 Nov;108(11):1577–83.
69. TRIPOD (The Troglitazone in Prevention of Diabetes) Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes*. 2002 Sep;51(9):2796–803.
70. UGDP (University group diabetes program). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. *Diabetes* 1970;19(2):747–830.
71. UKPDS (The United Kingdom Prospective Diabetes Study) Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med* 2008, 359(15):1565–1576.
72. VADT (Veterans Affairs Diabetes Trial) Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129–139.
73. VAHIT (Veteran Affairs – HDL cholesterol Intervention Trial) Rubins H, Robins S, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. *N Engl J Med*. 1999;341:410–8.
74. WHO DIAMOND Project (WHO Multinational Project for Childhood Diabetes). WHO Multinational Project for Childhood Diabetes. *Diabetes Care*. 1990 Oct;13(10):1062–8.
75. XENDOS (XENical in the prevention of Diabetes in Obese Subjects) Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*. 2004 Jan;27(1):155–61. Erratum in: *Diabetes Care*. 2004 Mar;27(3):856.
76. Metaanalýza. Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. *J Am Heart Assoc*. 2015 May 5;4(5).
77. Metaanalýza. Fang HJ, Zhou YH, Tian YJ, Du HY, Sun YX, Zhong LY. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. *Int J Cardiol*. 2016 Sep 1;218:50–58.
78. Metaanalýza. Odgers-Jewell K, Ball L, Kelly J, et al. Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression. *Diabet Med*. 2017;34:1027–39.